drugset

drugset / Trial / NCT04704713

Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)

NCT04704713 ↗

Phase 3 Completed 31 enrolled Clinuvel Pharmaceuticals Limited

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study was to evaluate the safety and efficacy of afamelanotide in patients suffering from polymorphic light eruption (PLE).

Timeline

Start: 2010-05-05
Primary completion: 2010-12-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Afamelanotide	Peptide	16 mg	Subcutaneous

Indications